We have a strong commitment to clinical research and actively support new and innovative treatments for retinal diseases. Our dedicated research unit is currently involved in a number of international clinical trials and programs involving patients with Age-Related Macular Degeneration, Diabetic Macular Oedema and Retinal Vein Occlusions. These studies are pivotal in quantifying the outcomes of current management and support the potential for future treatments.

Our retina specialists have wide-ranging experience in clinical trials and recognise the importance of research to promote understanding of eye disorders, investigate new therapeutic agents and advise patients on the best available treatment options.

Some patients enrolled in trials have the benefit of accessing new and advanced treatments during the final stages of development, prior to market release.


The AUSSIEDEX study aims to use prospective data to further advance the understanding of Dexamethasone in the treatment of diabetic macular oedema (DME) in Australia.


The ARIES study is a randomised study to compare the efficacy of Aflibercept for the management of Age-Related Macular Degeneration using a “treat and extend” regimen over two years.


The Sapphire study is a randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal triamcinolone acetonide injection in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion. We aim to extend the visit period by using newly developed suprachoroidal injection technique which improves overall patient compliance.

TOPAZ Study:

The Topaz study is a randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal Anti-VEGF agent in subjects with Retinal Vein Occlusion (RVO).

RHINE Study:

The Rhine study is a phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with Diabetic Macular Edema (DME)

OTX-TKI Study:

The OTX-TKI study is a phase 1 open-label, dose escalation study of OTX-TKI (axitinib implant) for intravitreal use in subjects with neovascular Age-related macular degeneration (AMD).

Completed Studies


The Uncover study is a retrospective analysis of clinical outcomes observed in patients with choroidal neovascularization (also known as CNV) secondary to age-related macular degeneration (AMD) being treated with Ranibizumab injections in a real-life clinical setting.


The LUMINOUS Study aims to observe the effectiveness and safety of using Ranibizumab injections as treatment for patients with wet form Age-Related Macular Degeneration, also known as wet AMD.


The purpose of the CONTROL Study is to evaluate the efficacy of Ranibizumab intravitreal injection in patients with Diabetic Macular Oedema (DMO) comparing both well controlled and poorly controlled diabetes mellitus.

Retinal Vein Occlusions (RVO) Study

The Retinal Vein Occlusions (RVO) study investigates the clinical outcomes of applying Ranibizumab intravitreal injections on patients with Retinal Vein Occlusions (RVO) in a real-life clinical setting.


The FLUID study is a randomised and controlled study aiming to investigate the efficacy and safety of using Ranibizumab injections in patients with wet Age-Related Macular Degeneration by comparing an “intensive” and a “relaxed” management of retinal fluid.


The PLANET study is a randomised study with the purpose of investigating the effectiveness, safety and tolerability of applying Aflibercept injections alone; as an adjunctive treatment with Photodynamic therapy in patients with a subtype of wet Age-Related Macular Degeneration, which is known as polypoidal choroidal vasculopathy (PCV).


The RIVAL Study is a randomised study which aims to compare the development of new geographic atrophy in patients who are treated with Ranibizumab versus those treated with Aflibercept for wet Age-Related Macular Degeneration.


The PROXIMA Study is a global, prospective, epidemiological study which aims to investigate the relationship between retinal anatomy and visual function in patients with bilateral geographic atrophy secondary to wet Age-Related Macular Degeneration.


SEQUOIA is a global, randomised, active controlled study which evaluates the safety and efficacy of Abicipar as a treatment for Neovascular Age-Related Macular Degeneration.